Exemptia 40mg Injection (Adalimumab)

Exemptia 40mg Injection is prescribed to treat multiple types of autoimmune and inflammatory diseases. It contains adalimumab as an active ingredient, which is a rheumatic agent that belongs to the class of drugs known as TNF (tumor necrosis factor) inhibitors. It can be used alone or with other medications to relieve the symptoms and manage the condition. The doctor prescribes Adalimumab 40mg injection in the treatment of certain autoimmune disorders such as rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, enthesitis-related arthritis, ankylosing spondylitis, psoriatic arthritis, plaque psoriasis, hidradenitis suppurativa, Crohn's disease, ulcerative colitis, and non-infectious uveitis.

The injection is administered subcutaneously by a qualified doctor in a hospital or clinical setting. The doctor determines the dosage of the Adalimumab 40mg injection according to the treatment regimen, age, and overall health of the patient. It should not be self-administered. Patients are advised not to change the dosage and timings prescribed by the doctors because it can cause severe side effects.

Common side effects include injection-site reactions, headache, upper respiratory tract infections, nausea, abdominal pain, and rash. A few patients can undergo severe side effects, including serious allergic reactions, hepatitis B reactivation, demyelinating disorders, heart failure and lupus-like syndrome. Most of the Adalimumab 40mg injection side effects can leave when the body adapts to the medicine. However, if any side effects persist, inform your doctor immediately.

Attend tests for tuberculosis and other active infections, and appropriate screening should be done. Live vaccines must be avoided during treatment. It should be stored refrigerated at 2°C–8°C, protected from light, and should not be frozen. Patients must list all medicines, supplements, and herbal products that they are taking. The Adalimumab 40mg injection must be used under medical oversight or medical supervision only. Attend regular tests and follow-ups to monitor the medicine response and reduce side effects. Before making any adjustments, changing the dose, or stopping the treatment, consult with your doctor to maximize the benefit.  

Rheumatoid arthritis

The human body reacts differently to the Exemptia 40mg Injection (Adalimumab 40mg). Response or undesired symptoms vary from individual to individual. Usually, they disappear with time as the body adjusts to the medicine.

These side effects don't need special medical attention. However, if the symptoms don't disappear with time or you have severe side effects, then consult your doctor immediately.​

Some of the common side effects of Exemptia 40mg:
● Injection site reactions
● Rash
● Headache
● Sinusitis
● Upper respiratory infections
● Fever

Some serious (rare) side effects:
● Heart problems
● Abnormal heartbeat
● Severe skin reactions
● GI bleeding
● Abnormal blood count values
● Liver injury
● Bone problems
● Infections
● Severe respiratory problems

The dosage of Exemptia 40mg Injection (Adalimumab 40mg) and the duration of treatment are decided by the doctor as per the type of autoimmune disorders and the patient's condition.

Exemptia 40mg should be injected subcutaneously as per the treatment strategy. Don't take this injection if you have active tuberculosis or other severe infections and moderate or severe heart failure.

● Jani, R. H., Gupta, R., Bhatia, G., Rathi, G., Ashok Kumar, P., Sharma, R., ... & Mendiratta, S. K. (2016). A prospective, randomized, double‐blind, multicentre, parallel‐group, active controlled study to compare efficacy and safety of biosimilar adalimumab (Exemptia; ZRC‐3197) and adalimumab (Humira) in patients with rheumatoid arthritis. International Journal of Rheumatic Diseases, 19(11), 1157-1168.
● Chandra, A., Kanth, R., & Thareja, S. (2019). Efficacy and safety of adalimumab Biosimilar (Exemptia) in moderate-to-severe Steroid-Refractory ulcerative colitis patients: real-life outcomes in resource-constrained setting at 24-Weeks follow-up. Biologics: Targets and Therapy, 191-200.
● Arvind, C., Khadke, N., Saluja, M., Kianifard, T., Venugopalan, A., & Chopra, A. Effectiveness of a Short Term Induction Regimen of a Biosimilar Adalimumab in the Long Term Management of Symptomatic Ankylosing Spondylitis: A Community Based Proof of Concept Observational Study.
● Komaki, Y., Yamada, A., Komaki, F., Kudaravalli, P., Micic, D., Ido, A., & Sakuraba, A. (2017). Efficacy, safety and pharmacokinetics of biosimilars of anti-tumor necrosis factor-α agents in rheumatic diseases; a systematic review and meta-analysis. Journal of autoimmunity, 79, 4-16.
● Yadav, K., Kuchya, S., & Kalyani, A. (2022). A Case Report Overwhelming response to TNF-alfa inhibitor Infliximab “innovator” Vs. Adalimumab “Bio-similar” in a previously therapy naive adult. Indian Journal of Case Reports, 8(3), 58-61.